24 April 2020

COVID-19 and the Pediatric Praziquantel Consortium

Over the last few weeks, the Pediatric Praziquantel Consortium has been working hard to map the impacts of the COVID-19 crisis on the project.

While it is not yet clear what the exact consequences will be, the team has been able to make a start on assessing the delays and the options for next steps.

For now, the pivotal clinical Phase III trials in Kenya and the Ivory Coast have been put on hold. Patient enrollment in these countries was paused on 22 March, in line with national restrictions. The situation in these countries will be re-evaluated in mid-May and project timelines will take into account the evolution of the situation.

Despite the setbacks caused by the COVID-19 pandemic, the Pediatric Praziquantel Consortium will continue to work towards achieving its aim of registering and providing access to a pediatric formulation of the drug praziquantel, so that the many millions of preschool-age children suffering from this debilitating disease can be cared for.